About Zinc finger protein 48
Zinc finger protein 48 (ZNF48) is a protein
from Homo sapiens identified by UniProt accession
Q96MX3, 618 residues long.
MolForge cross-references it against 0 known binders and
8 disease associations.
Target properties
| Protein name | Zinc finger protein 48 |
| UniProt accession | Q96MX3 |
| Gene | ZNF48 |
| Organism | Homo sapiens |
| Length | 618 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (8)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.44
- prostate carcinoma · score 0.11
- prostate cancer · score 0.11
- Familial prostate cancer · score 0.11
- blood protein measurement · score 0.03
- cardiac troponin I measurement · score 0.02
- Myopia · score 0.00
- myopia · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96MX3-F1 | alphafold | PREDICTED | 62.36 | — |
Amino-acid sequence (618 residues)
MERAVEPWGP DLHRPEEREP QRGARTGLGS ENVISQPNEF EHTPQEDDLG FKEEDLAPDH EVGNASLKPE GIQNWDDLWV QREGLGKPQP RDRGPRLLGE PRWGQASSDR AAVCGECGKS FRQMSDLVKH QRTHTGEKPY KCGVCGKGFG DSSARIKHQR THSGEKPYRA RPPAQGPPKI PRSRIPAGER PTICGECGKS FRQSSDLVKH QRTHTGEKPY KCGICGKGFG DSSARIKHQR THRGEQPPRP VVPRRQPSRA ATAATQGPKA QDKPYICTDC GKRFVLSCSL LSHQRSHLGP KPFGCDVCGK EFARGSDLVK HLRVHTGEKP YLCPECGKGF ADSSARVKHL RTHSGERPHA CPECDRTFSL SSTLLRHRLT HMEPQDFSFP GYPLPALIPS PPPPPLGTSP PLTPRSPSHS GEPFGLPGLE PEPGGPQAGE PPPPLAGDKP HKCPECGKGF RRSSDLVKHH RVHTGEKPYL CPECGKGFAD SSARVKHLRT HRGERARPPP PSTLLRPHNP PGPVPMAPRP RVRAQPSGPS QPHVCGFCGK EFPRSSDLVK HRRTHTGEKP YKCAECGKGF GDSSARIKHQ RGHLVLTPFG IGDGRARPLK QEAATGLE
Explore Zinc finger protein 48 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets